
Kaela E Goldstein

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/4653390/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	A Sensitive Whole Blood Assay Detects Antigen-Stimulated Cytokine Release From CD4+ T Cells and Facilitates Immunomonitoring in a Phase 2 Clinical Trial of Nexvax2 in Coeliac Disease. Frontiers in Immunology, 2021, 12, 661622.	4.8	14
2	Cytokine release after gluten ingestion differentiates coeliac disease from selfâ€reported gluten sensitivity. United European Gastroenterology Journal, 2020, 8, 108-118.	3.8	26
3	Masked bolus gluten challenge low in FODMAPs implicates nausea and vomiting as key symptoms associated with immune activation in treated coeliac disease. Alimentary Pharmacology and Therapeutics, 2020, 51, 244-252.	3.7	27
4	Patient factors influencing acute gluten reactions and cytokine release in treated coeliac disease. BMC Medicine, 2020, 18, 362.	5.5	22
5	Baseline quantitative histology in therapeutics trials reveals villus atrophy in most patients with coeliac disease who appear well controlled on glutenâ€free diet. GastroHep, 2020, 2, 22-30.	0.6	43
6	Elevated serum interleukinâ€2 after gluten correlates with symptoms and is a potential diagnostic biomarker for coeliac disease. Alimentary Pharmacology and Therapeutics, 2019, 50, 901-910.	3.7	51
7	Cytokine release and gastrointestinal symptoms after gluten challenge in celiac disease. Science Advances, 2019, 5, eaaw7756.	10.3	84
8	Epitope-specific immunotherapy targeting CD4-positive T cells in coeliac disease: two randomised, double-blind, placebo-controlled phase 1 studies. The Lancet Gastroenterology and Hepatology, 2017, 2, 479-493.	8.1	113
9	Epitope-Specific Immunotherapy Targeting CD4-Positive T Cells in Celiac Disease: Safety, Pharmacokinetics, and Effects on Intestinal Histology and Plasma Cytokines with Escalating Dose Regimens of Nexvax2 in a Randomized, Double-Blind, Placebo-Controlled Phase 1 Study. EBioMedicine, 2017. 26. 78-90.	6.1	51
10	Sa1395 Nexvax2®, a Peptide-Based Antigen-Specific Immunotherapy, Administered Intra-Dermally Three-Times Over 15-Days attenuates Responsiveness to Immuno-Dominant Gluten Peptides in HLA-DQ2.5+ People With Celiac Disease (CeD). Gastroenterology, 2016, 150, S304.	1.3	2